How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

76,786 results for

Cancer Prevention

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Sunitinib (Sutent) - to delay or prevent the return of kidney cancer

Sunitinib (Sutent) - to delay or prevent the return of kidney cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 27 July 2018 EMA/504631/2018 EMEA/H/C/000687/II/0065 Withdrawal of application for a change to the marketing (...) (tumours of the hormone-producing cells in the pancreas); • metastatic renal cell carcinoma (kidney cancer that has spread to other parts of the body). Sutent has been authorised since July 2006 and contains the active substance sunitinib. Further information on Sutent’s current uses can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. What was Sutent expected to be used for? Sutent was expected to be used to delay or prevent the return

2018 European Medicines Agency - EPARs

22. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors. (PubMed)

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors. Oral mucositis is a side effect of chemotherapy, head and neck radiotherapy, and targeted therapy, affecting over 75% of high-risk patients. Ulceration can lead to severe pain and difficulty with eating and drinking, which may necessitate opioid analgesics, hospitalisation and supplemental nutrition. These complications may disrupt cancer therapy, which may reduce survival (...) . There is also a risk of death from sepsis if pathogens enter the ulcers of immunocompromised patients. Ulcerative oral mucositis can be costly to healthcare systems, yet there are few preventive interventions proven to be beneficial. Cytokines and growth factors may help the regeneration of cells lining of the mouth, thus preventing or reducing oral mucositis and its negative effects.To assess the effects of cytokines and growth factors for preventing oral mucositis in patients with cancer who are receiving

Full Text available with Trip Pro

2017 Cochrane

23. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. (PubMed)

Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Tumour lysis syndrome (TLS) is a serious complication of malignancies and can result in renal failure or death. Previous reviews did not find clear evidence of benefit of urate oxidase in children with cancer. This review is the second update of a previously published Cochrane review.To assess the effects and safety of urate oxidase for the prevention and treatment of TLS in children (...) with malignancies.In March 2016 we searched CENTRAL, MEDLINE, Embase, and CINAHL. In addition, we searched the reference lists of all identified relevant papers, trials registers and other databases. We also screened conference proceedings and we contacted experts in the field and the manufacturer of rasburicase, Sanofi-aventis.Randomised controlled trials (RCT) and controlled clinical trials (CCT) of urate oxidase for the prevention or treatment of TLS in children under 18 years with any malignancy.Two review

2017 Cochrane

24. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication Final Update Summary: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication Release Date: April 2016 Recommendation (...) Summary Population Recommendation Grade Adults aged 50 to 59 years with a ≥10% 10-year CVD risk The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. Adults aged 60 to 69 years with a ≥10

2016 U.S. Preventive Services Task Force

25. Does vitamin B3 (nicotinamide) prevent non-melanoma skin cancer?

Does vitamin B3 (nicotinamide) prevent non-melanoma skin cancer? Does vitamin B3 (nicotinamide) prevent non-melanoma skin cancer? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/04\/PSX_20180428_214552.jpg"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Apr 30 2018 Does vitamin B3 (...) (nicotinamide) prevent non-melanoma skin cancer? By in , , Journal reference: Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine 2015 Oct 22;373(17):1618-26 Link: Published: October 2015 Evidence cookie says… Nicotinamide (vitamin B3) has a small-modest effect as prophylaxis against non-melanoma skin cancers the dose used in this study was 500 mg twice daily it reduced the number of new non-melanoma skin cancers

2018 Morsels of Evidence

26. Does vitamin B3 (nicotinamide) prevent non-melanoma skin cancer?

Does vitamin B3 (nicotinamide) prevent non-melanoma skin cancer? Does vitamin B3 (nicotinamide) prevent non-melanoma skin cancer? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/04\/PSX_20180428_214552.jpg"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Apr 30 2018 Does vitamin B3 (...) (nicotinamide) prevent non-melanoma skin cancer? By in , , Journal reference: Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine 2015 Oct 22;373(17):1618-26 Link: Published: October 2015 Evidence cookie says… Nicotinamide (vitamin B3) has a small-modest effect as prophylaxis against non-melanoma skin cancers the dose used in this study was 500 mg twice daily it reduced the number of new non-melanoma skin cancers

2018 Morsels of Evidence

27. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study

Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics:a dual cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could (...) , Anthony Howell 2, 3 1 Department of Genomic Medicine, Institute of Human Development, Manchester Academic Health Science Centre (MAHSC), Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK 2 Institute of Population Health, Centre for Imaging Sciences, University of Manchester, Manchester, UK 3 The Nightingale Centre and Genesis Prevention Centre, University Hospital of South Manchester, Manchester, UK 4 Department of Health Economics, University of Manchester, Manchester, UK 5

Full Text available with Trip Pro

2016 NIHR HTA programme

28. Skin Cancer Prevention: Behavioral Counseling

Skin Cancer Prevention: Behavioral Counseling Final Recommendation Statement: Skin Cancer Prevention: Behavioral Counseling - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Skin Cancer Prevention: Behavioral Counseling Recommendations made by the USPSTF are independent of the U.S. government. They should (...) cancer. See the section for information on risk assessment. Adults The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of counseling adults about skin self-examination to prevent skin cancer. See the section for suggestions for practice regarding the I statement. To read the recommendation statement in JAMA , select To read the evidence summary in JAMA , select . Table of Contents Preface The US Preventive Services Task Force (USPSTF) makes

2018 U.S. Preventive Services Task Force

29. The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations

The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different (...) surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A, Perera S, Wood J, Miles A, Wardle J, Kearns B, Tappenden P, Myles J, Veitch A & Duffy S W Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2017 Health Technology Assessment (HTA) Database.

30. Sun protection for preventing basal cell and squamous cell skin cancers. (PubMed)

Sun protection for preventing basal cell and squamous cell skin cancers. 'Keratinocyte cancer' is now the preferred term for the most commonly identified skin cancers basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), which were previously commonly categorised as non-melanoma skin cancers (NMSC). Keratinocyte cancer (KC) represents about 95% of malignant skin tumours. Lifestyle changes have led to increased exposure to the sun, which has, in turn, led to a significant (...) and barrier methods) for preventing keratinocyte cancer (that is, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) of the skin) in the general population.We searched the following databases up to May 2016: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trial registries and the bibliographies of included studies for further references to relevant trials.We included randomised controlled clinical trials (RCTs) of preventive

2016 Cochrane

31. Interventions for treating oral leukoplakia to prevent oral cancer. (PubMed)

Interventions for treating oral leukoplakia to prevent oral cancer. Oral leukoplakia is a relatively common oral lesion that, in a small proportion of people, precedes the development of oral cancer. Most leukoplakias are asymptomatic; therefore, the primary objective of treatment should be to prevent onset of cancer. This review updates our previous review, published in 2006.To assess the effectiveness, safety and acceptability of treatments for leukoplakia in preventing oral cancer.We (...) Platform for ongoing trials (to 16 May 2016). We placed no restrictions on the language or date of publication when searching electronic databases.We included randomised controlled trials (RCTs) that enrolled people with a diagnosis of oral leukoplakia and compared any treatment versus placebo or no treatment.We collected data using a data extraction form. Oral cancer development, demonstrated by histopathological examination, was our primary outcome. Secondary outcomes were clinical resolution

Full Text available with Trip Pro

2016 Cochrane

32. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. (PubMed)

Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different platinum infusion durations have been studied. This review is an update (...) of a previously published Cochrane review.To assess the effects of different durations of platinum infusion to prevent hearing loss or tinnitus, or both, in children with cancer. Secondary objectives were to assess possible effects of these infusion durations on: a) anti-tumour efficacy of platinum-based therapy, b) adverse effects other than hearing loss or tinnitus, and c) quality of life.We searched the electronic databases Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2016

Full Text available with Trip Pro

2016 Cochrane

33. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. (PubMed)

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of these, is used to treat a variety of paediatric malignancies. One of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different otoprotective medical interventions have been studied. This review is the second update of a previously (...) published Cochrane review.To assess the efficacy of medical interventions to prevent hearing loss and to determine possible effects of these interventions on anti-tumour efficacy, toxicities other than hearing loss and quality of life in children with cancer treated with platinum-based therapy.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 6), MEDLINE (PubMed) (1945 to 8 July 2016) and EMBASE (Ovid) (1980 to 8 July 2016). In addition, we handsearched reference lists

2016 Cochrane

34. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. (PubMed)

Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Neutropenia is a potentially serious side effect of chemotherapy and a major risk factor for infection, which can be life-threatening. It has been hypothesised that a low bacterial diet (LBD) can prevent infection and (infection-related) mortality in cancer patients receiving chemotherapy that causes episodes of neutropenia, but much remains unclear (...) . This review is an update of a previously published Cochrane review.The primary objective of this review was to determine the efficacy of an LBD versus a control diet in preventing infection and in decreasing (infection-related) mortality in adult and paediatric cancer patients receiving chemotherapy that causes episodes of neutropenia. Secondary objectives were to assess time to first febrile episode, need for empirical antibiotic therapy, diet acceptability and quality of life.We searched the following

2016 Cochrane

35. Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. Exposure to UV radiation, especially in childhood, increases skin cancer risk.To systematically review the evidence on the benefits and harms of behavioral counseling for skin cancer prevention to inform the US Preventive Services Task Force (USPSTF).Cochrane Central Register of Controlled Trials, MEDLINE, and PubMed were searched for studies published from January (...) 2009 to March 31, 2016, for skin cancer prevention and from August 2005 to March 31, 2016, for skin self-examination. Surveillance in targeted publications was conducted through February 14, 2018. Studies included in previous USPSTF reports were reevaluated for inclusion.Fair- and good-quality studies of primary care-relevant behavioral interventions focused on improving skin cancer outcomes, intermediate outcomes, or skin cancer prevention and self-examination behaviors.Two investigators

Full Text available with Trip Pro

2018 JAMA

36. Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. (PubMed)

Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. Skin cancer is the most common type of cancer in the United States. Although invasive melanoma accounts for only 2% of all skin cancer cases, it is responsible for 80% of skin cancer deaths. Basal and squamous cell carcinoma, the 2 predominant types of nonmelanoma skin cancer, represent the vast majority of skin cancer cases.To update the 2012 US Preventive Services Task Force (USPSTF (...) ) recommendation on behavioral counseling for the primary prevention of skin cancer and the 2009 recommendation on screening for skin cancer with skin self-examination.The USPSTF reviewed the evidence on whether counseling patients about sun protection reduces intermediate outcomes (eg, sunburn or precursor skin lesions) or skin cancer; the link between counseling and behavior change, the link between behavior change and skin cancer incidence, and the harms of counseling or changes in sun protection behavior

Full Text available with Trip Pro

2018 JAMA

37. Adherence to The World Cancer Research Fund/American Institute for Cancer Research 2018 Recommendations for Cancer Prevention and Risk of Colorectal Cancer. (PubMed)

Adherence to The World Cancer Research Fund/American Institute for Cancer Research 2018 Recommendations for Cancer Prevention and Risk of Colorectal Cancer. The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) 2018 diet, nutrition, and physical activity recommendations aim to reduce cancer risk. We examined adherence to the WCRF/AICR recommendations and colorectal cancer (CRC) risk in two prospective cohorts.We followed 68,977 women in the Nurses' Health Study (...) ); we did not observe significant differences between anatomic locations in women.The 2018 WCRF/AICR cancer prevention recommendations are associated with lower CRC risk in men, with weaker results in women.Consideration of adiposity and physical activity in conjunction with diet is important for CRC prevention.Copyright ©2019, American Association for Cancer Research.

2019 Cancer Epidemiology & Biomarkers and Prevention

38. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Common osteoporosis drugs may prevent breast cancer spreading to bone Discover Portal Discover Portal Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 doi: Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may (...) be small, for example preventing spread to bone or death in about one extra woman in every 100 treated for about five years. This is a complex area because many of the treatments for breast cancer are known to worsen bone thinning, but there are other bone strengthening benefits to these drugs. This large review of 44 studies with more than 37,000 participants looked at women with either early breast cancer or advanced breast cancer with or without bone involvement. The reviewers also concluded

2019 NIHR Dissemination Centre

39. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update.

Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective (...) for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P, Orsey A, Portwine C, Freedman J, Madden JR, Phillips R, Sung L, Dupuis LL. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer. 2017 Oct;64(10) [48 references] This is the current release of the guideline. This guideline updates

2017 National Guideline Clearinghouse (partial archive)

40. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer

Clinical practice guidelines for the prevention, early detection and management of colorectal cancer Clinical practice guidelines for the prevention, early detection and management of colorectal cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer (...) , and developed for health professionals practising in an Australian health care setting. This publication reflects the views of the authors and not necessarily the views of the Australian Government. Cite this guideline Cancer Council Australia Colorectal Referring to the large bowel, comprising the colon and rectum. Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia. [Version URL: , cited

2017 Clinical Practice Guidelines Portal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>